INBIOMED

What INBIOMED does

INBIOMED (Instituto de Investigaciones Biomédicas) is a public biomedical research institute operating as a Unidad Ejecutora jointly administered by Universidad de Buenos Aires (UBA) and CONICET, located at Paraguay 2155, Buenos Aires, Argentina. Founded in 2005, the institute is staffed by approximately 30+ CONICET career researchers, 30+ doctoral and postdoctoral fellows, 8 technical support personnel, and 2 administrative staff, distributed across the 5th and 10th floors of UBA's Faculty of Medicine. Its research spans cancer biology (breast, colon, prostate, adrenocortical, glioblastoma), neurodegenerative diseases (Huntington's, Alzheimer's), reproductive biology (male and female infertility, endometriosis), molecular endocrinology, toxicology, cytogenetics, and signal transduction, with core technical approaches spanning molecular biology, gene therapy, histology, electron microscopy, immunohistochemistry, bioinformatics, cell culture, animal models, and nanotechnology-based therapeutics.

The institute's proprietary platforms include the ACSL4 tumor-aggressiveness program (with granted US Patent US 9737515 B2 and two PCT applications covering ACSL4 inhibitors for breast, colon, prostate, and adrenocortical cancers), baculovirus and lentiviral gene therapy vectors targeting glioblastoma and breast cancer (Humanin, prolactin receptor, CXCR4-CXCL12 pathways), nanotechnology-based drug carriers (PEO-PPO copolymers, thermosensitive copolymers, synthetic protein nanoparticles), the experimental autoimmune orchitis (EAO) preclinical model, and mGlu3R/mGlu3Δ44 biomarker research for Alzheimer's disease. Outputs include 150+ peer-reviewed publications, multiple granted and pending patents, and trained doctoral/postdoctoral researchers.

INBIOMED's revenue model is non-commercial and government-anchored: primary funding flows from CONICET institutional appropriations, UBA budgets, and competitive research grants (ANPCyT PICT, CONICET PIP, UBA UBACyT, plus international grants from IBRO, ISN, and CAEN). A modest third-party services line (Servicios a Terceros) generates fee-based revenue through hereditary cancer mutation detection, testicular biopsy analysis for infertility diagnosis, and histological preparation (STAN de Histología). The institute has no equity ownership, no commercial product distribution, and no M&A activity; its strategic direction is set within the CONICET/UBA institutional framework.

Name

INBIOMED

Legal name

Instituto de Investigaciones Biomédicas

Website

https://inbiomed.conicet.gov.ar

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

INBIOMED is a public biomedical research institute jointly run by Universidad de Buenos Aires and CONICET in Argentina, conducting fundamental and applied research in cancer, neurodegeneration, reproductive biology, and endocrinology while offering diagnostic laboratory services and patent-licensed therapeutic candidates.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Government institutional funding: INBIOMED is a public research unit (Unidad Ejecutora) funded primarily through government appropriations from CONICET and Universidad de Buenos Aires, including salaries for CONICET researchers and operational grants.
2. Research project grants: Funding from ANPCyT (Agencia Nacional de Promoción Científica y Tecnológica), CONICET PIP projects, UBA UBACyT grants, and international sources (IBRO, ISN, CAEN) support specific research projects.
3. Third-party services (Servicios a Terceros): The institute provides paid laboratory services to external clients, including detection of mutations predisposing to hereditary cancer and analysis of testicular biopsies, generating service revenue.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

INBIOMED is a public biomedical research institute that conducts fundamental and applied research in cancer biology, neurodegenerative diseases, reproductive biology, molecular endocrinology, toxicology, and cytogenetics. It offers third-party laboratory services including hereditary cancer mutation detection and testicular biopsy analysis, plus histological preparation services (STAN de Histología). The institute also delivers doctoral and postdoctoral research training through CONICET and UBA fellowship programs.

Product overview

INBIOMED is a biomedical research institute (Instituto de Investigaciones Biomédicas) affiliated with Universidad de Buenos Aires and CONICET. It functions as a research and service institution rather than a commercial technology company. The institute provides scientific services to third parties, including genetic testing for hereditary cancer mutations, testicular biopsy analysis, and histological preparation services (STAN de Histología). Research activities focus on various areas including oncology, neuroscience, reproductive biology, and environmental toxicology.

Differentiator

Problem solved

Functional benefit

Products and services

• Detección de mutaciones que predisponen al cáncer hereditario
• Análisis de biopsias de testículo
• STAN de Histología (ST6217)

Quantifiable outcome

• ACSL4 inhibitor was shown to reduce breast and prostate tumor growth in preclinical models and reverse therapeutic resistance and steroidogenesis.
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas)coreStrategic or Co-development Partner · 1 July 2026CONICET is the national scientific research council of Argentina and INBIOMED's primary institutional parent. As a 'Unidad Ejecutora,' INBIOMED operates under CONICET's administrative and funding framework. CONICET provides researcher salaries, operational grants, and research project funding (PIP). The relationship is foundational to the institute's existence and operations.
• University of Turin (Università degli Studi di Torino)minorStrategic or Co-development Partner · 1 July 2026CONICET and the University of Turin have strengthened scientific ties through a bilateral cooperation agreement, within which INBIOMED researchers participate.
• CONFAP (Brazilian National Council of State Foundations for Scientific and Technological Research)minorStrategic or Co-development Partner · 1 July 2026CONICET and CONFAP of Brazil signed a scientific and technological cooperation agreement, potentially involving joint research projects with INBIOMED researchers.
• Universidad de Buenos Aires (UBA)coreStrategic or Co-development PartnerUniversidad de Buenos Aires is the second institutional parent of INBIOMED. The institute is physically located within the Faculty of Medicine of UBA, and researchers hold academic appointments (professors, instructors) at UBA alongside their CONICET positions. UBA co-funds research projects through UBACyT grants.
• Pontificia Universidad Católica de ChileminorStrategic or Co-development PartnerDra. Daniela Durand conducted an international research internship at this institution, representing a bilateral research exchange.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Regional players

• Fiocruz (Fundação Oswaldo Cruz): Brazilian public research and health technology foundation covering biomedical research, diagnostics, and vaccine development. Comparable as a Latin American public biomedical research organization with both research and service mandates.

Broad incumbents

• INSERM: French national institute for health and medical research. Comparable as a publicly funded biomedical research organization, but operates at much larger scale and with a broader translational mandate than INBIOMED.
• NIH (National Institutes of Health): U.S. government biomedical research agency. Comparable only at the broadest level as a publicly funded biomedical research system; orders of magnitude larger than INBIOMED and not a direct competitor.
• Max Planck Society (biomedical sections): German public research organization with institutes covering molecular biomedicine, biology of ageing, and related fields. Comparable in scientific breadth and quality, but vastly larger in funding and headcount than INBIOMED.

Direct peers

• IBR-CONICET (Instituto de Biología Molecular y Celular de Rosario): CONICET institute in Rosario with strong programs in molecular and cell biology, structural biology, and signal transduction. Comparable as a public research unit producing peer-reviewed publications and training doctoral fellows.
• ININFA (Instituto de Investigaciones Farmacológicas): CONICET-UBA pharmacology research institute with a similar public-institute structure, third-party services program, and translational research mandate, directly comparable to INBIOMED's drug discovery and applied therapeutic work.
• Fundación Instituto Leloir: Buenos Aires-based biomedical research institute focused on molecular biology and disease mechanisms. Comparable in scale, funding model (mix of public grants and philanthropic support), and emphasis on fundamental-to-translational research.
• IBYME (Instituto de Biología y Medicina Experimental): Sister CONICET-UBA biomedical research institute located in Buenos Aires. Operates under the same Unidad Ejecutora model with overlapping research lines in endocrinology, reproductive biology and cancer, making it the most structurally and scientifically comparable peer.
• CIBICI-CONICET: CONICET-UNC biochemistry and clinical immunology research institute in Córdoba. Comparable in its mix of basic biomedical research, graduate training, and provision of specialized laboratory services to external clients.
• INGEBI-CONICET: CONICET institute dedicated to genetics, molecular biology and biotechnology in Buenos Aires. Directly comparable as a public research unit producing peer-reviewed science, patents, and doctoral training.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inbiomed-ar
• Instagraminstagram.com/inbiomed.ar

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INBIOMED